Role of the nicotinic acetylcholine receptor in Alzheimer's disease pathology and treatment
| Autor: | Uwe Maskos, Sylvia Lombardo |
|---|---|
| Přispěvatelé: | Neurobiologie intégrative des Systèmes cholinergiques (NISC), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), SL was supported by EU FP7 'BRAINTRAIN', Fondation pour la Recherche Médicale FRMand Institut Pasteur programme 'PasteurInnov' 2012, European Project: 238055,EC:FP7:PEOPLE,FP7-PEOPLE-ITN-2008,BRAINTRAIN(2009), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS) |
| Jazyk: | angličtina |
| Rok vydání: | 2015 |
| Předmět: |
Pathology
medicine.medical_specialty Nicotine Mice Transgenic Receptors Nicotinic Cellular and Molecular Neuroscience Alzheimer Disease mental disorders Muscarinic acetylcholine receptor medicine Muscarinic acetylcholine receptor M4 Animals Humans Nicotinic Agonists Pharmacology Neurons Amyloid beta-Peptides Muscarinic acetylcholine receptor M3 Brain medicine.disease Receptors Muscarinic 3. Good health Nicotinic acetylcholine receptor Disease Models Animal Nicotinic agonist Cholinergic [SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC] Alzheimer's disease Psychology Neuroscience Acetylcholine medicine.drug |
| Zdroj: | Neuropharmacology Neuropharmacology, 2015, The Nicotinic Acetylcholine Receptor: From Molecular Biology to Cognition, 96 (Pt B), pp.255-62. ⟨10.1016/j.neuropharm.2014.11.018⟩ Neuropharmacology, Elsevier, 2015, The Nicotinic Acetylcholine Receptor: From Molecular Biology to Cognition, 96 (Pt B), pp.255-62. ⟨10.1016/j.neuropharm.2014.11.018⟩ |
| ISSN: | 0028-3908 |
| DOI: | 10.1016/j.neuropharm.2014.11.018⟩ |
| Popis: | International audience; Alzheimer's Disease (AD) is the major form of senile dementia, characterized by neuronal loss, extracellular deposits, and neurofibrillary tangles. It is accompanied by a loss of cholinergic tone, and acetylcholine (ACh) levels in the brain, which were hypothesized to be responsible for the cognitive decline observed in AD. Current medication is restricted to enhancing cholinergic signalling for symptomatic treatment of AD patients. The nicotinic acetylcholine receptor family (nAChR) and the muscarinic acetylcholine receptor family (mAChR) are the target of ACh in the brain. Both families of receptors are affected in AD. It was demonstrated that amyloid beta (Aβ) interacts with nAChRs. Here we discuss how Aβ activates or inhibits nAChRs, and how this interaction contributes to AD pathology. We will discuss the potential role of nAChRs as therapeutic targets. This article is part of the Special Issue entitled 'The Nicotinic Acetylcholine Receptor: From Molecular Biology to Cognition'. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect